cholecystectomy and glp 1 GLP-1 receptor agonists gallbladder disease risk: insights into molecular mechanisms and clinical implications Gallbladder Risks with GLP-1 Medications

DPP4 is involved in the degradation of GLP-1, GIP, as well as glucagon to biologically inactive fragments

View at Publisher | View at Google Scholar World Health Organization

Importantly, the nuance in offering GLP-1s is that employers want to ensure they get into the hands of the employees that stand to benefit most and thus get the most value out of the medicines, so I expect we will see additional restrictions put in place to control coverage of these medicines, in the form of prior authorizations and other controlled access

Coordination involves discussing whether postponing elective surgery by weeks to months helps metabolic stabilization, or if discontinuing a medication sooner lowers particular risk

As usual Professor Galloway has been worthwhile following as he informed me early in the GLP-1 adoption curve to pay attention to what has gone beyond a medical trend to a cultural and economic phenomenon